Author + information
- Zhu Jianbing and
- Junbo Ge
The aim of this study was to conduct a network meta-analysis comparing biodegradable-polymer drug-eluting stents versus bare metal stents versus durable-polymer drug-eluting stents in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
We included data from 30 randomized controlled trials (RCT) involving 30,186 patients. The incidence of stent thrombosis (ST) was the primary endpoint. Target vessel revascularization (TVR) was the secondary endpoint of the efficacy.
Compared with BMS, biodegradable polymer drug-eluting stents (OR: 0.48, 95% credible interval (CrI): 0.37-0.99), durable-polymer drug-eluting stents (OR: 0.58, 95% CrI, 0.48-0.86) resulted in lowwer risk of ST within 1 year. Biodegradable polymer-biolimus-eluting stents was associated with a higher risk of TVR than cobalt-chromium everolimus-eluting (CoCr-EES) (OR: 1.62, 95% CrI: 1.14-2.56).
Biodegradable polymer drug-eluting stents was superior to BMS, but higher risk of TVR comparing to durable-polymer drug-eluting stents, in terms of ST within 1 year with the lower risk of ST.